Acquire the license to the best health content in the world
Contact Us

Risk of Infection, Malignancy With Anti-TNF Therapy Unclear

No raised risk in early rheumatoid arthritis patients, naive to methotrexate

FRIDAY, March 11 (HealthDay News) -- Patients with early rheumatoid arthritis taking anti-tumor necrosis factor (TNF) therapy without prior use of disease-modifying anti-rheumatic drugs (DMARD)/methotrexate do not have an increased risk of serious infections or malignancies, according to a meta-analysis published online Feb. 25 in Arthritis & Rheumatism.

Andrew E. Thompson, M.D., from the University of Western Ontario in London, Canada, and colleagues conducted a meta-analysis of six randomized, double-blind, placebo-controlled trials to determine the rates of serious infection and malignancy in patients with early rheumatoid arthritis who started anti-TNF therapy without prior DMARD/methotrexate use. A total of 2,183 patients receiving biologic therapy and 1,236 patients receiving methotrexate therapy were included. The risk of serious infection and malignancy was measured using a pooled odds ratio (OR).

The investigators found that there was a slightly higher, but not statistically significant, risk of serious infections requiring hospitalization (pooled OR, 1.16) and malignancies (pooled OR, 1.07) in patients receiving anti-TNF therapy compared to patients receiving methotrexate (controls).

"This meta-analysis has not shown an increased risk of malignancy or serious infections in newly diagnosed patients with rheumatoid arthritis treated with anti-TNF therapy. However, further review of this population of patients in an observational inception cohort would be important to confirm and strengthen these findings," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing